
CLAIMS

1. A compound, or a pharmaceutically acceptable salt thereof, represented by formula II:



(II)

wherein:

X represents CH, C(OH), C(O(C_1-C_6)alkyl), -C(NH_2), -C(NR^aR^b), -C(N_3), -C(CN), -C(NO_2), -C($S(O)_nR^a$), -C[-C(=O)R^c], -C[-C(=O)R^c], -C[-C(=O)NR^cR^d], -C[-C(=O)SR^c], -C[-S(O)R^c], -C[-$S(O)_2R^c$], -C[S(O)(OR^c)], -C[-$S(O)_2$(OR^c)], -C[-$SO_2NR^cR^d$], -C(halogen), -C[(C_1-C_8)alkyl], -C[(C_4-C_8)carbocyclyl], -C[(C_1-C_8)substituted alkyl], -C[(C_2-C_8)alkenyl], -C[(C_2-C_8)substituted alkenyl], -C[(C_2-C_8)alkynyl], -C[(C_2-C_8)substituted alkynyl], -C[aryl(C_1-C_8)alkyl], C(O)N, CH_2N, N, C(O), P(O), -O-, S(O)N, or $S(O)_2$N; provided that:

if X represents CH, then -Y-R^4 represents -H or -OH, or both Y and R^4 are present;

if X represents C(OH), C(O(C_1-C_6)alkyl), -C(NH_2), -C(NR^aR^b), -C(N_3), -C(CN), -C(NO_2), -C($S(O)_nR^a$), -C[-C(=O)R^c], -C[-C(=O)R^c], -C[-C(=O)NR^cR^d], -C[-C(=O)SR^c], -C[-S(O)R^c], -C[-$S(O)_2R^c$], -C[S(O)(OR^c)], -C[-$S(O)_2$(OR^c)], -C[-$SO_2NR^cR^d$], -C(halogen), -C[(C_1-C_8)alkyl], -C[(C_4-C_8)carbocyclyl], -C[(C_1-C_8)substituted alkyl], -C[(C_2-C_8)alkenyl], -C[(C_2-C_8)substituted alkenyl], -C[(C_2-C_8)alkynyl], -C[(C_2-C_8)substituted alkynyl], or -C[aryl(C_1-C_8)alkyl], then -Y-R^4 is present;

if X represents C(O)N, then -Y-R^4 represents H; or -Y-R^4 represents H, and -R^3-R^{3a} represents H;

if X represents CH_2N, then -Y-R^4 represents (C_1-C_6)alkyl;

if X represents N, then -Y-R^4 represents H, or both Y and R^4 are present; and

if X represents C(O) or -O-, then -Y-R^4 is absent;


-Y-R^4, when present, represents -((C_1-C_6)alkyl)-R^4, -$CH_2C(O)$-R^4, -CH_2NH-R^4, -CH_2N((C_1-C_6)alkyl)-R^4, -CR^aR^b-R^4, -NH-R^4, -$NHCH_2$-R^4, -NHC(O)-R^4, -N((C_1-C_6)alkyl)-R^4, -N((C_1-C_6)alkyl)CH_2-R^4, -N((CH_2)$_2$OH)-R^4, -N[(C_3-C_8)cycloalkyl(C_1-C_6)alkyl]R^4, -heterocyclyl-R^4, -OR^4, -OCH_2-R^4, -OC(O)-R^4, -$OC(O)NR^aR^b$, -SCH_2R^4, or -SR^4, wherein the (C_1-C_6)alkyl moiety of -((C_1-C_6)alkyl)-R^4 is optionally substituted;
Z is absent or represents one or more substituents independently selected from the group consisting of halo, hydroxy, (C_1-C_6)alkyl, -CF_3, -OCF_3, (C_1-C_6)alkoxy, aryl, aryloxy, amino, amino(C_1-C_6)alkyl, -$C(O)NH_2$, cyano, -NHC(O)(C_1-C_6)alkyl, -SO_2(C_1-C_6)alkyl, -SO_2NH_2, (C_3-C_8)cycloalkyl, $(CH_2)_rOR^a$, NO_2, $(CH_2)_r$ NR^aR^b, $(CH_2)_rC(O)R^a$, $NR^aC(O)R^b$, $C(O)NR^cR^d$, $NR^aC(O)NR^cR^d$, -$C(=NR^a)NR^cR^d$, $NHC(=NR^a)NR^cR^d$, NR^aR^b, $SO_2NR^cR^d$, $NR^aSO_2NR^cR^d$, NR^aSO_2-(C_1-C_6)alkyl, $NR^aSO_2R^a$, $S(O)_pR^a$, $(CF_2)_rCF_3$, $NHCH_2R^a$, OCH_2R^a, SCH_2R^a, $NH(CH_2)_2(CH_2)_rR^a$, $O(CH_2)_2(CH_2)_rR^a$, and $S(CH_2)_2(CH_2)_rR^a$; or alternatively Z is a 5- or 6-membered aromatic heterocycle containing from 1 to 4 heteroatoms selected from the group consisting of N, O, and S;
R^{1c} represents halo, amino(C_1-C_6)alkyl, (C_1-C_6)alkoxy, cyano, -$C(=NH)NH_2$, -$CONR^aR^b$, -(C_1-C_6)alkyl$CONR^aR^b$, -SO_2CH_3, formyl, acyl, -NH_2, -C(=NH)NH(OH), -C(=NH)NH(C(O)O-(C_1-C_6)alkyl), -C(=NH)NH(C(O)O-(C_1-C_6)haloalkyl), -C(=NH)NH(C(O)S-(C_1-C_6)alkyl), -C(=NH)NH(C(O)(OCH(C_1-C_6)alkyl)OC(O)(C_1-C_6)alkyl), optionally substituted aryl, or optionally substituted heteroaryl;
R^2 represents halo, (C_1-C_6)alkyl, (C_3-C_8)cycloalkyl, (C_1-C_6)fluoroalkyl, -OCH_3, -$Si(CH_3)_3$, -$CONH_2$, -C(O)OH, cyano, or phenyl;
R^3, when present, represents -NH-, -O-, optionally substituted aryl, heteroaryl, phenyl, carbocyclyl, or heterocyclyl;
R^{3a} is absent or represents one or more substituents independently selected from the group consisting of halo, hydroxy, (C_1-C_6)alkyl, -CF_3, -OCF_3, (C_1-C_6)alkoxy, aryl, aryloxy, amino, amino(C_1-C_6)alkyl, -$C(O)NH_2$, cyano, -NHC(O)(C_1-C_6)alkyl, -SO_2(C_1-C_6)alkyl, -SO_2NH_2, (C_3-C_8)cycloalkyl, $(CH_2)_rOR^a$, NO_2, $(CH_2)_r$ NR^aR^b, $(CH_2)_rC(O)R^a$, $NR^aC(O)R^b$, $C(O)NR^cR^d$, $NR^aC(O)NR^cR^d$, -$C(=NR^a)NR^cR^d$, $NHC(=NR^a)NR^cR^d$, NR^aR^b, $SO_2NR^cR^d$, $NR^aSO_2NR^cR^d$, NR^aSO_2-(C_1-C_6)alkyl, $NR^aSO_2R^a$, $S(O)_pR^a$, $(CF_2)_rCF_3$, $NHCH_2R^a$, OCH_2R^a, SCH_2R^a, $NH(CH_2)_2(CH_2)_rR^a$, $O(CH_2)_2(CH_2)_rR^a$, or


$S(CH_2)_2(CH_2)_rR^a$; or alternatively R^{3a} is a 5- or 6-membered aromatic heterocycle containing from 1 to 4 heteroatoms selected from the group consisting of N, O, and S;


R^4 represents hydrogen, hydroxy, optionally substituted $(C_1\text{-}C_6)$alkyl, optionally substituted $(C_3\text{-}C_8)$cycloalkyl, heterocyclyl$(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_8)$cycloalkyl$(C_1\text{-}C_6)$alkyl, -CH_2OH, -CH($(C_1\text{-}C_6)$alkyl)OH, -$CH(NH_2)CH((C_1\text{-}C_6)alkyl)_2$, optionally substituted aryl, optionally substituted aryl$(C_1\text{-}C_6)$alkyl, heteroaryl, optionally substituted heteroaryl$(C_1\text{-}C_6)$alkyl, -$CH_2S(C_1\text{-}C_6)$alkyl, amino, or cyano; or -$(CR^aR^b)_r(CR^aR^b)_p$- fused to the 4-position of the ring bearing Z to form a 5- to 7-membered heterocyclic ring with optional substituents; or, when R^3 is phenyl, can represent -NR^a- fused to the position *ortho* to X on that phenyl;


each R^a and R^b is independently H, $(C_1\text{-}C_8)$alkyl, $(C_2\text{-}C_8)$alkenyl, $(C_2\text{-}C_8)$alkynyl, aryl$(C_1\text{-}C_8)$alkyl, $(C_3\text{-}C_8)$carbocyclyl, -$C(=O)R^c$, -$C(=O)OR^c$, -$C(=O)NR^cR^d$, -$C(=O)SR^c$, -$S(O)R^c$, -$S(O)_2R^c$, -$S(O)(OR^c)$, or –$SO_2NR^cR^d$;

each R^c and R^d is independently H, $(C_1\text{-}C_8)$alkyl, $(C_2\text{-}C_8)$alkenyl, $(C_2\text{-}C_8)$alkynyl, $(C_4\text{-}C_8)$ carbocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -$C(=O)(C_1\text{-}C_8)$alkyl, -$S(O)_n(C_1\text{-}C_8)$alkyl, or aryl$(C_1\text{-}C_8)$alkyl; or when R^c and R^d are bonded to a common nitrogen atom, then they may form a 3- to 7-membered heterocyclic ring wherein optionally a carbon atom of said heterocyclic ring may be replaced with -O-, -S- or -NR^a-;



can represent


,


, or


;


n is 2 or 3;

r is independently for each occurrence 0, 1, 2, or 3;

p is independently for each occurrence 0, 1, or 2; and

the stereochemical configuration at any chiral center is *R*, *S*, or a mixture of *R* and *S*.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, represented by formula III:



(III)

wherein:

X represents CH, C(OH), C(O(C_1-C_6)alkyl), C(O)N, CH_2N, N, C(O), or -O-;


-Y-R^4, when present, represents -((C_1-C_6)alkyl)-R^4, -CH_2C(O)-R^4, -CH_2NH-R^4, -CH_2N((C_1-C_6)alkyl)-R^4, -CR^aR^b-R^4, -NH-R^4, -$NHCH_2$-R^4, -NHC(O)-R^4, -N((C_1-C_6)alkyl)-R^4, -N((C_1-C_6)alkyl)CH_2-R^4, -N((CH_2)$_2$OH)-R^4, -N[(C_3-C_8)cycloalkyl(C_1-C_6)alkyl]R^4, -heterocyclyl-R^4, -OR^4, -OCH_2-R^4, -OC(O)-R^4, -$OC(O)NR^aR^b$, -SCH_2R^4, or -SR^4, wherein the (C_1-C_6)alkyl moiety of -((C_1-C_6)alkyl)-R^4 is optionally substituted;


Z is absent or represents halo, hydroxy, (C_1-C_6)alkyl, -CF_3, -OCF_3, (C_1-C_6)alkoxy, aryl, aryloxy, amino, amino(C_1-C_6)alkyl, -$C(O)NH_2$, cyano, -NHC(O)(C_1-C_6)alkyl, -SO_2(C_1-C_6)alkyl, -SO_2NH_2, or (C_3-C_8)cycloalkyl;


R^{1c} represents halo, amino(C_1-C_6)alkyl, (C_1-C_6)alkoxy, cyano, -SO_2CH_3, formyl, acyl, or optionally substituted aryl;


R^{3a} is absent or represents one or more substituents independently selected from the group consisting of halo, hydroxy, (C_1-C_6)alkyl, -CF_3, -OCF_3, (C_1-C_6)alkoxy, aryl, aryloxy, amino, amino(C_1-C_6)alkyl, -$C(O)NH_2$, cyano, -NHC(O)(C_1-C_6)alkyl, -SO_2(C_1-C_6)alkyl, and -SO_2NH_2;

R^4 represents hydrogen, hydroxy, optionally substituted (C_1-C_6)alkyl, optionally substituted (C_3-C_8)cycloalkyl, heterocyclyl(C_1-C_6)alkyl, (C_3-C_8)cycloalkyl(C_1-C_6)alkyl, -CH_2OH, -CH((C_1-C_6)alkyl)OH, -$CH(NH_2)CH((C_1$-C_6)alkyl)$_2$, optionally substituted aryl, optionally substituted aryl(C_1-C_6)alkyl, heteroaryl, optionally substituted heteroaryl(C_1-C_6)alkyl, -CH_2S(C_1-C_6)alkyl, amino, or cyano; or -CH_2- fused to the 4-position of the ring bearing Z to form a 5- to 7-membered heterocyclic ring with optional substituents; or, when R^3 is phenyl, can represent -NH- fused to the position *ortho* to X on that phenyl; and



can represent


,



, or



.


3. The compound of claim 1 or 2, wherein X represents CH, and both Y and R^4 are present.


4. The compound of claim 1 or 2, wherein -X-Y- represents -$CHNHCH_2$-, -$C(OH)CH_2CH_2$-, or -$CHOCH_2$-.


5. The compound of claim 1 or 2, wherein R^3 represents phenylene-R^{3a}.


6. The compound of claim 1 or 2, wherein -R^3-R^{3a} represents



,



,



,



,



,


,



,



,


,



, or






.

7. The compound of claim 1 or 2, wherein -R^3-R^{3a} represents


or


.

8. The compound of claim 1 or 2, wherein -R^3-R^{3a} represents ,

, , , or .

9. The compound of claim 1 or 2, wherein R^4 is cyclopropyl.

10. The compound of claim 1 or 2, wherein R^3 is phenyl, and R^{3a} is *ortho*, *meta*, or *para* -OH.

11. The compound of claim 1 or 2, wherein R^3 is phenyl, and R^{3a} is *meta* or *para* -NH_2.

12. The compound of claim 1 or 2, wherein R^3 is phenyl, and R^{3a} is *meta* or *para* -CN.

13. The compound of claim 1 or 2, wherein Z is absent.

14. The compound of claim 1 or 2, wherein Z represents fluoro.

15. The compound of claim 1 or 2, wherein Z represents chloro.

16. The compound of claim 1 or 2, wherein Z represents 2-F, 4-F, 5-F, 6-F, 6-Cl, or 5-(C_3-C_8)cycloalkyl.


17. The compound of claim 1 or 2, wherein R^{1c} represents aminomethyl.

18. The compound of claim 1 or 2, wherein R^{1c} represents cyano.


19. The compound of claim 1 or 2, wherein R^{1c} represents -SO_2CH_3.

20. The compound of any one of claims 1-19, wherein R^2 is -CH_3, -CF_3, *tert*-butyl, cyclopropyl, -OCH_3, -$Si(CH_3)_3$, -$CONH_2$, cyano, or phenyl.


21. The compound of claim 1 or 2, wherein said compound is selected from the group consisting of:




,










,
















,




,


,

,

,

,

,

,

,


,

,

,

,

,


,

,

,

,

,

,

, and

.

22. A compound, or a pharmaceutically acceptable salt thereof, represented by formula XXVI:



(XXVI)

wherein:

X represents CH, C(OH), -C(NH_2), or -C(NR^aR^b);

-Y-R^4, when present, represents -((C_1-C_6)alkyl)-R^4, -CH_2C(O)-R^4, -CH_2NH-R^4, -CH_2N((C_1-C_6)alkyl)-R^4, -CR^aR^b-R^4, -NH-R^4, -$NHCH_2$-R^4, -NHC(O)-R^4, -N((C_1-C_6)alkyl)-R^4, -N((C_1-C_6)alkyl)CH_2-R^4, -N((CH_2)$_2$OH)-R^4, -N[(C_3-C_8)cycloalkyl(C_1-C_6)alkyl]R^4, -heterocyclyl-R^4, -OR^4, -OCH_2-R^4, -OC(O)-R^4, -OC(O)NR^aR^b, -SCH_2R^4, or -SR^4, wherein the (C_1-C_6)alkyl moiety of -((C_1-C_6)alkyl)-R^4 is optionally substituted;

Z is absent or represents halo, hydroxy, (C_1-C_6)alkyl, -CF_3, -OCF_3, (C_1-C_6)alkoxy, aryl, aryloxy, amino, amino(C_1-C_6)alkyl, -C(O)NH_2, cyano, -NHC(O)(C_1-C_6)alkyl, -SO_2(C_1-C_6)alkyl, -SO_2NH_2, or (C_3-C_8)cycloalkyl;

R^{1c} represents halo, amino(C_1-C_6)alkyl, (C_1-C_6)alkoxy, cyano, -SO_2CH_3, formyl, acyl, -NH_2, or optionally substituted aryl;

R^2 represents halo, (C_1-C_6)alkyl, (C_3-C_8)cycloalkyl, (C_1-C_6)fluoroalkyl, -OCH_3, -Si(CH_3)$_3$, -$CONH_2$, -C(O)OH, cyano, or phenyl;









R^3 represents -NH-, -O-, optionally substituted aryl, heteroaryl, phenyl, carbocyclyl, or heterocyclyl;





R^{3a} is absent or represents one or more substituents independently selected from the group consisting of halo, hydroxy, (C_1-C_6)alkyl, -CF_3, -OCF_3, (C_1-C_6)alkoxy, aryl, aryloxy, amino, amino(C_1-C_6)alkyl, -C(O)NH_2, cyano, -NHC(O)(C_1-C_6)alkyl, -SO_2(C_1-C_6)alkyl, and -SO_2NH_2; and

R^4 represents hydrogen, hydroxy, optionally substituted (C_1-C_6)alkyl, optionally substituted (C_3-C_8)cycloalkyl, heterocyclyl(C_1-C_6)alkyl, (C_3-C_8)cycloalkyl(C_1-C_6)alkyl, -





CH_2OH, -CH((C_1-C_6)alkyl)OH, -CH(NH_2)CH((C_1-C_6)alkyl)$_2$, optionally substituted aryl, optionally substituted aryl(C_1-C_6)alkyl, heteroaryl, optionally substituted heteroaryl(C_1-C_6)alkyl, -CH_2S(C_1-C_6)alkyl, amino, or cyano; or -CH_2- fused to the 4-position of the ring bearing Z to form a 5- to 7-membered heterocyclic ring with optional substituents; or, when R^3 is phenyl, can represent -NH- fused to the position *ortho* to X on that phenyl;
each R^a and R^b is independently H, (C_1-C_8)alkyl, (C_2-C_8)alkenyl, (C_2-C_8)alkynyl, aryl(C_1-C_8)alkyl, (C_3-C_8)carbocyclyl, -C(=O)R^c, -C(=O)OR^c, -C(=O)N$R^c$$R^d$, -C(=O)S$R^c$, -S(O)$R^c$, -S(O)$_2$$R^c$, -S(O)(O$R^c$), or –$SO_2NR^c$$R^d$;
each R^c and R^d is independently H, (C_1-C_8)alkyl, (C_2-C_8)alkenyl, (C_2-C_8)alkynyl, (C_4-C_8) carbocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -C(=O)(C_1-C_8)alkyl, -S(O)$_n$(C_1-C_8)alkyl, or aryl(C_1-C_8)alkyl; or when R^c and R^d are bonded to a common nitrogen atom, then they may form a 3- to 7-membered heterocyclic ring wherein optionally a carbon atom of said heterocyclic ring may be replaced with -O-, -S- or -NR^a-;
n is 2 or 3; and
the stereochemical configuration at any chiral center is *R*, *S*, or a mixture of *R* and *S*.









23. The compound of claim 22, wherein said compound is selected from the group consisting of:










,

,

,

,

,

,

,

,










,

,

, and

.







24. The compound of claim 1, wherein said compound is selected from the group consisting of:










,

,

,

,










,

,

,

,

,

,

,

,












,

,

,

,

,

,

,

,












,

,

,

,

,

,

,

,



























,

,

,

,

,

,

,

,










,

,

,

,

,

,

,

,
- 878 -










,

,

,

,

,

,

,

,

,

,









,

,

,

,

,

,

,

,

,

,










,

,

,

,

,

,

,

,

,

,











,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,








,

,

,

,

,

,

,

,


,

,

,

,

,

,

,


,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

, and

.

25. A pharmaceutical composition, comprising a compound of any one of claims 1-24; and a pharmaceutically acceptable carrier.

26. The pharmaceutical composition of claim 25, wherein the pharmaceutical composition is formulated for parenteral administration.

27. The pharmaceutical composition of claim 25, wherein the pharmaceutical composition is formulated for oral administration.

28. The compound of any one of claims 1-24, for use as a medicament in treating or preventing a disease or condition characterized by unwanted plasma kallikrein activity; wherein the disease or condition characterized by unwanted plasma kallikrein activity is selected from the group consisting of stroke, inflammation, reperfusion injury, acute myocardial

infarction, deep vein thrombosis, post fibrinolytic treatment condition, angina, edema, angioedema, hereditary angioedema, sepsis, arthritis, hemorrhage, blood loss during cardiopulmonary bypass, inflammatory bowel disease, diabetes mellitus, retinopathy, diabetic retinopathy, diabetic macular edema, diabetic macular degeneration, age-related macular edema, age-related macular degeneration, proliferative retinopathy, neuropathy, hypertension, brain edema, increased albumin excretion, macroalbuminuria, and nephropathy.

29. The compound for use of claim 28, wherein the disease or condition characterized by unwanted plasma kallikrein activity is angioedema.

30. The compound for use of claim 28, wherein the disease or condition characterized by unwanted plasma kallikrein activity is hereditary angioedema.

31. The compound of any one of claims 1-24, for use as a medicament.